Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer
Daryush Purrahman, Mohammad‐Reza Mahmoudian‐Sani, Najmaldin Saki, Piotr Wojdasiewicz, Iwona Kurkowska‐Jastrzębska, Łukasz A. Poniatowski
Abstract
Breast cancer constitute a common type of oncological disease with a highlighted mortality rate. In recent years, researchers have introduced progranulin (PGRN) as an novel potential biomarker and associated its function with higher risk factor for development of breast cancer. The present review article collects evidence on the association of PGRN with clinicopathological features and drug resistance in the patients with breast cancer. The results of this study suggested the use of routine determination of PGRN in the clinic as a reliable biomarker for screening people at high risk or as early indication of breast cancer. Targeting PGRN and its associated signaling pathways and receptors, such as sortilin (SORT1), could also cover a novel therapeutic strategy in the breast cancer.